CRSP vs EDIT
CRSP and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $5.02B | $420.81M |
| P/S | 1431.2x | 10.4x |
| Revenue growth (YoY) | -90.6% | 25.4% |
| Earnings growth (YoY) | -58.8% | 32.5% |
| EBIT margin | -18933.6% | -394.9% |
| ROE | -35.3% | -152.0% |
| ROIC | -32.5% | — |
| 1y total return | -8.1% | -1.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: CRSP frente a EDIT
| Métrica | CRSP | EDIT |
|---|---|---|
| Valor final | $36.7K | $2.0K |
| Retorno total | +267.5% | -80.5% |
| CAGR | +13.8% | -15.0% |
| Volatilidad | 63.9% | 84.3% |
| Sharpe | 0.45 | 0.16 |
| Sortino | 0.70 | 0.25 |
| Caída máxima | -85.1% | -98.9% |
Basado en 2525 días de negociación comunes, 2016-10-19 → 2026-11-04 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)